Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Stellar Biotechnologies has acquired an exclusive sub-licensable and royalty-free license to the technology developed through a collaborative research agreement between Stellar and Bayer Innovations (BIG).
Subscribe to our email newsletter
The license includes a carve-out by BIG for use of the technology in its non-Hodgkin lymphoma (NHL) vaccine which is currently under development.
The license leaves Stellar free to commercialise the technology, exclusively, in all other fields.
Stellar CEO Frank Oakes said the technology developed through the collaboration with BIG represents a breakthrough in the production of characterised, immunogenically potent carrier proteins (ICPs), not only in terms of quality and purity, but also for cost management in the final drug product.
"The technology will be integrated into BIG’s NHL vaccine platform, and commercialised broadly by Stellar for other vaccines and related products," Oakes said.